ASCO Annual Meeting Coverage
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine.
In a time of internal transition, Roche emphasized its deep roots and broad pipeline at its annual event alongside the American Society for Clinical Oncology meeting.
Latest From ASCO
Analysis presented at ASCO concludes that pilot program helped physicians request access to investigational drugs for individual patients. Now agency officials are suggesting an expansion of the project.
Research presented at the American Society for Clinical Oncology annual meeting evaluates cancer drug costs and benefits using two value frameworks meant to assist physicians and patients in treatment decisions.
Keeping Track: Tecentriq, Cyramza Celebrate ASCO With New Indications; Brilinta Moves Earlier In Coronary Artery Disease
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new selective estrogen receptor degraders for HER2-negative breast cancer.
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.